Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 2/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631215 | 0.92 | MAPK14 (0.53) | MLLT1MAPK14MAPK13CHRNA7CHRNB2 | |
| SCHEMBL6633464 | 0.83 | CHRNA7 (0.41) | MAPK13CHRNA7CHRNB2CHRNA4CNR1 | |
| SCHEMBL6756936 | 0.82 | CHRNA7 (0.52) | CHRNA7CHRNB2CHRNA4CNR1CNR2 | |
| SCHEMBL6631573 | 0.81 | CHRNA7 (0.41) | CHRNA7CHRNB2CHRNA4CNR1CNR2 | |
| SCHEMBL6636133 | 0.80 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BCHRNB4CHRNA3 | |
| SCHEMBL6843525 | 0.80 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BCHRNB4CHRNA3 | |
| SCHEMBL6654035 | 0.80 | CHRNA7 (0.40) | CHRNA7CHRNB2CHRNA4CNR1CNR2 | |
| SCHEMBL6758236 | 0.79 | CHRNA7 (0.42) | CHRNA7CHRNB2CHRNA4CNR1CNR2 | |
| SCHEMBL6632431 | 0.79 | CHRNA7 (0.63) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL6755113 | 0.79 | CHRNA7 (0.53) | CHRNA7CHRNB2CHRNA4CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828330-B2 | Central nervous system disorders; schizophrenia; psychological disorders | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | claimed |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | claimed |
| EP-1404674-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | claimed |
| WO-2002100858-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| US-6828330-B2 | Central nervous system disorders; schizophrenia; psychological disorders | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | MLLT1 1080/4885KDM2B 3153/4885MAPK14 4793/4885 |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | MLLT1 1080/4885KDM2B 3153/4885MAPK14 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.